Brand Intelligence Graph
Company Overview
About Oxford Nanopore Technologies
Oxford Nanopore Technologies (ONT) was spun out of the University of Oxford in 2005, commercializing a radically different sequencing approach: passing DNA strands through biological nanopore proteins embedded in a membrane and detecting characteristic ionic current changes to call bases in real time. This enables ultra-long reads (megabase scale), direct RNA sequencing, and epigenetic base modification detection without prior amplification.
Business Model & Competitive Advantage
ONT's product range spans from the palm-sized MinION (the world's first portable DNA sequencer) to the high-throughput PromethION 2 Solo and PromethION 48 platforms. These instruments have enabled field sequencing for infectious disease outbreak response (COVID-19, mpox, Ebola), real-time clinical microbiology, plant pathogen surveillance, and cancer genomics. The company reported £223 million in FY2025 revenue, representing 24% constant-currency growth, with clinical revenues up 60% and biopharma revenues up 30%.
Competitive Landscape 2025–2026
ONT is publicly listed on the London Stock Exchange and holds approximately £300 million in cash. While accuracy has historically lagged Illumina and PacBio, successive chemistry improvements and the Kit14 chemistry have closed the gap for many applications. The company is expanding its presence in clinical diagnostics, with regulatory filings underway in key markets, and remains the benchmark for portable, real-time, and long-read sequencing.
Key Differentiators
Growth Stage
Oxford Nanopore Technologies has achieved $223M in revenue, demonstrating strong product-market fit.
Frequently Asked Questions
Estimated Visibility Trend (Beta)
Simulated 8-week rolling score
Based on estimated brand signals. Historical tracking coming soon.
Similar Brands
Pacific Biosciences
Illumina
Illumina was founded in 1998 in San Diego and has grown into the undisputed leader in next-generation sequencing (NGS), with approximately 80% global market share across research and clinical applicat
10x Genomics
10x Genomics was founded in 2012 in Pleasanton, California by Serge Saxonov, Ben Hindson, and Kevin Ness. The company developed the Chromium platform for single-cell RNA sequencing (scRNA-seq), enabli
Schrödinger
Schrödinger was founded in 1990 by Richard Friesner and David Pearlman in New York City, building physics-based computational methods for molecular simulation. For over 30 years the company has develo
Emulate
Emulate, Inc. is a Boston-based biotechnology company that designs, manufactures, and commercializes Organ-Chip technology — micro-engineered devices lined with living human cells that replicate the m
Florence Healthcare
Florence Healthcare is the dominant software platform for clinical trial site enablement, providing digital tools that connect trial sites, sponsors, and contract research organizations (CROs) to stre
Compare Oxford Nanopore Technologies with Competitors
Side-by-side AI visibility scores, platform breakdown, and market position.
Claim This Profile
Are you from Oxford Nanopore Technologies? Claim your profile to see full AI mention excerpts, get weekly visibility change alerts, and optimize how AI systems describe your brand.
Claim Oxford Nanopore Technologies Profile →Track AI Visibility in Real Time
Monitor how ChatGPT, Gemini, Perplexity, and Claude mention Oxford Nanopore Technologies vs competitors. Get alerts when AI recommendations shift.
Start Free Tracking →